IFNGR1 and myeloid sarcoma: While IFN-γ administration in MS patients and EAE mice exacerbates neuroinflammation and clinical symptoms [57–59], IFN-γ and IFNGR knockout mice exhibit increased susceptibility to EAE, with heightened morbidity and mortality [60–62].